Categories: News

Rapid Micro to Announce Third Quarter 2021 Financial Results on November 11, 2021

Conference Call to Discuss Results on November 12, 2021 at 5:00am Pacific Time/8:00am Eastern Time

LOWELL, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro” or the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will release financial results for the third quarter of 2021 after market close on Thursday, November 11, 2021.

Conference Call Details

Company management will host a webcast conference call to discuss third quarter 2021 financial results beginning at 5:00am Pacific Time/8:00am Eastern Time on Friday, November 12, 2021. The conference call will be available to interested parties via live webcast on the Company’s website at https://investors.rapidmicrobio.com/. The webcast will then be archived and available for replay for at least 90 days following the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct® System automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct® System brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.

CONTACT: Investor Contact:
David Deuchler
Gilmartin Group LLC
investors@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

Staff

Recent Posts

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7…

2 hours ago

RiDYMO® Designs Cyclic Peptide for “Undruggable” β-Catenin Target Within Two Months

BEIJING, Jan. 8, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has…

4 hours ago

ITRI Opens CES 2025 With Trend-Leading Showcase and Partnership With Reliance Biotech Corporation

LAS VEGAS, Jan. 8, 2025 /PRNewswire/ -- The Industrial Technology Research Institute (ITRI) initiated its presence…

4 hours ago

NOTICE OF DATA BREACH

LOS ANGELES, Jan. 8, 2025 /PRNewswire/ -- Dear members of the STIIIZY community:  Stiiizy, Inc.…

4 hours ago

Ascent Strategy Group Recognized by Modern Healthcare’s Best in Business, Affirms Health Equity Mission Amid Alarming Disparities

Agency Founder nominated Outstanding Agency Professional, Innovator of the Year First public relations agency built…

4 hours ago

Onco-Innovations Provides Information Regarding Exclusive License for Patented Drug with Potential to Enhance Cancer Treatment Options

VANCOUVER, BC / ACCESSWIRE / January 8, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or…

7 hours ago